摘要
肿瘤生物治疗是在肿瘤免疫治疗基础上发展起来的一种新的治疗方法，其特征是用生物学的手段（包括生物工程产品及方法）治疗患者以达到消灭肿瘤的目的。由于它与传统的手术、化疗及放疗有明显区别，所以被称为肿瘤的“第四种治疗模式”。但生物治疗在临床应用中也暴露出一...
出处
《医学研究生学报》
CAS
1998年第1期61-62,共2页
Journal of Medical Postgraduates
同被引文献14
-
1[1]David JS,Maurizio TN. The emerging roles of Gemcitabine and MTA in the treatment of non-small cell lung cancer[J]. Semi Oncol, 1999, 26(suppl4):1-2.
-
2[2]Akerly W, Glantz M, Choy H, et al. Phase Ⅱ trail of weekly paclitaxel in advanced non-small cell lung cancer[J]. J Clin Oncol, 1998, 16:153-158.
-
3[3]Perng RP, Chen YM, Ming L, et al. Gemcitabine versus the combination of cisplatin and etoposide in patients with inoperable non-small cell lung cancer in a phase Ⅱ randomized study[J]. J Clin Oncol, 1997, 15:2097-2102.
-
4[4]Baker L, Khan R, Lynch T, et al. Phase Ⅱ study of CPT-11 in advanced non-small cell lung cancer[J]. Proc Am Soc Clin Oncol, 1997, 16:1658.
-
5[5]Spiridonidas CH, Laufman LR, Jones J, et al. Phase Ⅱ trial of dailyX4 Navelbine-cisplatin in advanced non-small cell lung cancer:a preliminary report[J]. Prot Am Soc Clin Oncol, 1997, 16:1737.
-
6[6]Belani CP, Bonomi P, Dobbs T, et al. Docetaxel and cisplatin combination in patients with non-small cell lung cancer: a multicenter phase Ⅱ trial[J]. Lung Cancer, 1997,18:12-13.
-
7[7]Devore R, Crowford J, Dimery J, et al. Phase Ⅱ trial of irinotecan(CPT-11) plus cisplatin in advanced non-small cell lung cancer[J]. Prot Am Soc Clin Oncol, 1997, 16:1674.
-
8[8]Cardenal F. Paz LM, Anton A, et al, Randomized phase Ⅲ study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small cell lung cancer[J]. J Clin Oncol, 1999, 17:12-18.
-
9[9]Masuda N, Negoro S, Kudoh S, et al. Phase I and pharmacologic study of docetaxel and irinotecan in advanced non-small cell lung cancer[J]. J Clin Oncol, 2000, 18:2996-3003.
-
10[10]Frasci G, Lorusso V, Panza N, et al. Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small cell lung cancer[J]. J Clin Oncol, 2000, 13:2529-2536.
-
1杨波,李玉伟.贝伐单抗联合化疗治疗进展期非小细胞肺癌的现状与前景[J].西南军医,2012,14(2):330-332.
-
2杨四旬,谢蜀生.肿瘤基因治疗的现状与前景[J].科技导报,1993,11(2):36-39. 被引量：2
-
3夏海龙,姚程,易永林.PCR检测白血病和微小残留病的现状与前景[J].国外医学（输血及血液学分册）,1991,14(6):348-350.
-
4王敬慧,许国祥.非小细胞肺癌新辅助化疗及化放疗的现状与前景[J].结核病与胸部肿瘤,2003(4):353-361.
-
5周四维.浅表性膀胱癌规范化治疗现状与前景[J].现代泌尿外科杂志,2005,10(6):311-313. 被引量：13
-
6Kanz,L8,黄成龙.细胞因子联用的现状与前景[J].国外医学（军事医学分册）,1992,9(3):120-122.
-
7赵体平.肿瘤治疗的现状与前景[J].肿瘤,1990,10(6):281-283. 被引量：2
-
8龚镭,诸玲,胥明.胰腺癌基因治疗的现状与前景[J].胰腺病学,2005,5(1):56-57.
-
9顾琴龙,刘逸菲.肿瘤基因治疗的产生、现状与前景[J].医学与哲学,1993,14(3):11-13. 被引量：1
-
10杨伟炎.从专题会看经鼻垂体瘤手术及颅底外科的现状与前景[J].中华耳鼻咽喉科杂志,1996,31(5):259-260.
